Condition
High-risk HPV (Any Strain)
Total Trials
3
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting1
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07572396Phase 2RecruitingPrimary
Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients With High-Risk HPV (Hr-HPV) and Either (1) ASC-US or (2) Low-Grade Squamous Intraepithelial Lesions (LSIL)
NCT07303751Phase 2Not Yet Recruiting
Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV
NCT02354534Phase 1Completed
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
Showing all 3 trials